Volume 21, Issue 2, Pages (February 2013)

Slides:

Advertisements

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Advertisements

Central Venous Catheter Malposition Presenting as Chest Pain

Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector Wei Huang, Travis McMurphy,

Volume 20, Issue 2, (February 2012)

Volume 17, Issue 2, Pages (February 2009)

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

Molecular Therapy - Methods & Clinical Development

414. A Novel Clinical Severity Scoring Measure in Canine X-Linked Myotubular Myopathy: Results Following Systemic AAV Gene Replacement Molecular Therapy

Volume 7, Issue 1, Pages (January 2003)

Volume 20, Issue 2, Pages (February 2012)

Genome-editing Technologies for Gene and Cell Therapy

Volume 18, Issue 2, Pages (February 2010)

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Direct Conversion of Skin Cells into Blood: Alchemy or Science?

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

Enhanced Factor VIII Heavy Chain for Gene Therapy of Hemophilia A

FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B

Volume 16, Issue 2, Pages (February 2008)

Volume 20, Issue 5, Pages (May 2012)

Volume 26, Issue 2, Pages (February 2018)

Oral Administration of Recombinant Adeno-associated Virus-mediated Bone Morphogenetic Protein-7 Suppresses CCl4-induced Hepatic Fibrosis in Mice Zhi-Ming.

Volume 24, Issue 5, Pages (May 2016)

Volume 23, Issue 12, Pages (December 2015)

Volume 20, Issue 2, Pages (February 2012)

Volume 19, Issue 11, Pages (November 2011)

Volume 20, Issue 10, Pages (October 2012)

Volume 18, Issue 6, Pages (June 2010)

Volume 18, Issue 11, Pages (November 2010)

Volume 18, Issue 2, Pages (February 2010)

Volume 17, Issue 2, Pages (February 2009)

Molecular Therapy - Methods & Clinical Development

Genome-editing Technologies for Gene and Cell Therapy

Volume 22, Issue 5, Pages (May 2014)

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

Volume 12, Issue 6, Pages (December 2005)

Volume 18, Issue 1, Pages (January 2010)

Volume 19, Issue 8, Pages (August 2011)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Designer Lipids Advance Systemic siRNA Delivery

133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy Molecular.

Volume 18, Issue 1, Pages (January 2010)

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

Volume 16, Issue 6, Pages (June 2008)

Computer-assisted Hydrodynamic Gene Delivery

Volume 18, Issue 11, Pages (November 2010)

405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement Molecular.

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

Volume 19, Issue 7, Pages (July 2011)

Volume 19, Issue 6, Pages (June 2011)

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Volume 18, Issue 8, Pages (August 2010)

Volume 18, Issue 3, Pages (March 2010)

372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency Molecular.

Volume 1, Issue 2, Pages (February 2000)

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Volume 17, Issue 1, Pages (January 2009)

Volume 20, Issue 3, Pages (March 2012)

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Volume 18, Issue 12, Pages (December 2010)

Volume 18, Issue 6, Pages (June 2010)

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

Volume 22, Issue 2, Pages (February 2014)

Volume 19, Issue 5, Pages (May 2011)

Volume 16, Issue 4, Pages (April 2008)

Zhijian Wu, Aravind Asokan, R. Jude Samulski Molecular Therapy

Thomas Gaj, Benjamin E Epstein, David V Schaffer Molecular Therapy

Volume 16, Issue 4, Pages (April 2008)

Volume 18, Issue 2, Pages (February 2010)

Presentation transcript:

Volume 21, Issue 2, Pages 318-323 (February 2013) Minimizing the Inhibitory Effect of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated Virus 8 Vectors Jun Mimuro, Hiroaki Mizukami, Shuji Hishikawa, Tomokazu Ikemoto, Akira Ishiwata, Asuka Sakata, Tsukasa Ohmori, Seiji Madoiwa, Fumiko Ono, Keiya Ozawa, Yoichi Sakata Molecular Therapy Volume 21, Issue 2, Pages 318-323 (February 2013) DOI: 10.1038/mt.2012.258 Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Expression of FIX T262A in macaques after direct vector injection into portal veins. Macaques (n = 3) were subjected to direct injection of AAV8 vector into the portal vein. Concentrations of FIX T262A in macaque plasma samples (macaque #26, open triangles; #27, open circles; #29, closed squares) were measured by ELISA. AAV, adeno-associated virus; ELISA, enzyme-linked immunosorbent assay; FIX, factor IX. Molecular Therapy 2013 21, 318-323DOI: (10.1038/mt.2012.258) Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Fluorography in macaque #37. A balloon catheter was inserted into the portal vein of macaque #37 and contrast medium injected before vector administration. The left portal vein branches can be visualized. The arrow (white) indicates the tip of the catheter. See Supplementary Video S1 which also recorded inflation of the balloon before the vector administration and deflation of the balloon after the administration. Molecular Therapy 2013 21, 318-323DOI: (10.1038/mt.2012.258) Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Expression of FIX T262A in macaques following balloon catheter-guided vector injection into portal veins. Three macaques (n = 3) were subjected to balloon catheter-guided vector injection into the portal vein. Concentrations of FIX T262A in macaque plasma samples (#37, closed circles; #38, open squares; #42, closed triangles) were measured by ELISA. ELISA, enzyme-linked immunosorbent assay; FIX, factor IX. Molecular Therapy 2013 21, 318-323DOI: (10.1038/mt.2012.258) Copyright © 2013 The American Society of Gene & Cell Therapy Terms and Conditions